SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Triclabendazole / Abamectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
Company: MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone: 353-51-601000
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Specific target organ toxicity - repeated exposure, Category 2: H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1: H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1: H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:

Signal word: Warning

Hazard statements:
- H373: May cause damage to organs through prolonged or repeated exposure.
- H410: Very toxic to aquatic life with long lasting effects.

Precautionary statements:
Prevention:
Triclabendazole / Abamectin Formulation

P273 Avoid release to the environment.

Response:
P314 Get medical advice/attention if you feel unwell.
P391 Collect spillage.

Hazardous components which must be listed on the label:
Triclabendazole

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>606-143-00-0</td>
<td></td>
<td></td>
<td>STOT RE 2; H373 (Liver, Blood)</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>71751-41-2</td>
<td>606-143-00-0</td>
<td></td>
<td></td>
<td>Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Rep. 2; H361fd STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000</td>
<td>&gt;= 0,0025 - &lt; 0,025</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Triclabendazole / Abamectin Formulation

Version 1.6  Revision Date: 27.08.2021  SDS Number: 5342053-00007  Date of last issue: 26.04.2021  Date of first issue: 05.12.2019

| specific concentration limit | STOT RE 1; H372 >= 5 % | STOT RE 2; H373 0,5 - < 5 % |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray  Alcohol-resistant foam  Carbon dioxide (CO2)
Safety Data Sheet
according to Regulation (EC) No. 1907/2006

Triclabendazole / Abamectin Formulation

Version 1.6
Revision Date: 27.08.2021
SDS Number: 5342053-00007
Date of last issue: 26.04.2021
Date of first issue: 05.12.2019

Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides
Nitrogen oxides (NOx)
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Triclabendazole / Abamectin Formulation

Version 1.6 Revision Date: 27.08.2021 SDS Number: 5342053-00007 Date of last issue: 26.04.2021 Date of first issue: 05.12.2019

mine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Occupational Exposure Limits</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
<td>CAS-No.</td>
<td>Value type (Form of exposure)</td>
</tr>
<tr>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>TWA</td>
</tr>
</tbody>
</table>
Further information: DSEN

<table>
<thead>
<tr>
<th>Substance</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silicon dioxide</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>4 mg/m3</td>
</tr>
<tr>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium citrate</td>
<td>Fresh water</td>
<td>0.44 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.044 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td>Fresh water sediment</td>
<td></td>
<td>34.6 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Marine water</td>
<td>3.46 mg/kg dry weight (d.w.)</td>
<td></td>
</tr>
<tr>
<td>Soils</td>
<td>31.1 mg/kg dry weight (d.w.)</td>
<td></td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Eye protection

Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.
Skin and body protection: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to EN 143.

Filter type: Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

- **Physical state**: suspension
- **Colour**: white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **Melting point/freezing point**: < 5 °C
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Flash point**: No data available
- **Auto-ignition temperature**: No data available
- **Decomposition temperature**: No data available
- **pH**: 5.0 - 7.0
- **Viscosity**: No data available
- **Viscosity, kinematic**: No data available
- **Solubility(ies)**
  - **Water solubility**: soluble
- **Partition coefficient: n-octanol/water**: Not applicable
- **Vapour pressure**: No data available
- **Relative density**: No data available
Density : 1.050 - 1.080 g/cm³ (20 °C)
Relative vapour density : No data available
Particle characteristics
Particle size : Not applicable

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Triclabendazole:
Acute oral toxicity: LD50 (Mouse): > 8,000 mg/kg
     LD50 (Rabbit): 206 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0,5 mg/l
     Exposure time: 4 h
     Test atmosphere: dust/mist
     Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rat): > 4,000 mg/kg

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Acute oral toxicity: LD50 (Rat): 24 mg/kg
     LD50 (Mouse): 10 mg/kg
     LDLo (Monkey): 24 mg/kg
     Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0,023 mg/l
     Exposure time: 4 h
     Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg
     LD50 (Rabbit): 2,000 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Triclabendazole:**
Species: Rabbit
Result: Mild skin irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Species: Rabbit
Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Triclabendazole:**
Species: Rabbit
Result: No eye irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Triclabendazole:
Result: Not a skin sensitizer.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Triclabendazole:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative
Carcinogenicity
Not classified based on available information.

Components:
Triclabendazole:
Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:
Triclabendazole:
Effects on fertility
Test Type: Fertility/early embryonic development
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 5,5 mg/kg body weight

Effects on foetal development
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 200 mg/kg body weight
Result: Effects on foetal development
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: Effects on foetal development
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 3 mg/kg body weight
Remarks: Maternal toxicity observed.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0,12 mg/kg body weight
Result: Fetotoxicity

Effects on foetal development: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight
Developmental Toxicity: NOAEL: 0,2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1,6 mg/kg body weight
Result: Teratogenic effects
Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Triclabendazole:
Target Organs: Liver, Blood
Assessment: May cause damage to organs through prolonged or repeated exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Exposure routes: Ingestion
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Triclabendazole:
Species: Rat
NOAEL: 6.6 mg/kg
LOAEL: 69 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Blood

Species: Dog
NOAEL: 3.4 mg/kg
LOAEL: 37 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Liver, Blood

Species: Mouse
NOAEL: 29 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Liver

Species: Rat
NOAEL: 4 mg/kg
Application Route: Oral
Exposure time: 24 Months
Remarks: No significant adverse effects were reported

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>4.0 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, weight loss</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.0 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**
Not classified based on available information.

### 11.2 Information on other hazards

**Endocrine disrupting properties**

**Product:**

Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**Experience with human exposure**

**Components:**

**Triclabendazole:**

Ingestion: Symptoms: Abdominal pain, Sweating, Headache, Nausea,
Vomiting, anorexia, Dizziness, Fatigue, Cough, Fever, pruritis

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Ingestion: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h
LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h
LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h
LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h
LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h
EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity): 10.000

Toxicity to microorganisms: EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity): NOEC: 0.52 µg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.03 µg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
NOEC: 0.0035 µg/l
Exposure time: 28 d  
Species: Mysidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic toxicity) : 10.000

12.2 Persistence and degradability

**Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Stability in water : Hydrolysis: 50 %(< 12 h)

12.3 Bioaccumulative potential

**Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Bioaccumulation : Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water : log Pow: 4

12.4 Mobility in soil

**Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Distribution among environmental compartments : log Koc: > 3,6

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available
SECTION 13: Disposal considerations

13.1 Waste treatment methods

<table>
<thead>
<tr>
<th>Product</th>
<th>Waste treatment methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product</td>
<td>Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</td>
</tr>
<tr>
<td>Contaminated packaging</td>
<td>Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.</td>
</tr>
</tbody>
</table>

SECTION 14: Transport information

14.1 UN number or ID number

| ADN | UN 3082 |
| ADR | UN 3082 |
| RID | UN 3082 |
| IMDG | UN 3082 |
| IATA | UN 3082 |

14.2 UN proper shipping name

| ADN | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| ADR | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| RID | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| IMDG | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| IATA | Environmentally hazardous substance, liquid, n.o.s. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |

14.3 Transport hazard class(es)

| ADN | 9 |
| ADR | 9 |
| RID | 9 |
Triclabendazole / Abamectin Formulation

| IMDG | : 9 |
| IATA | : 9 |

### 14.4 Packing group

**ADN**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**ADR**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9
- Tunnel restriction code: (-)

**RID**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**IMDG**
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F

**IATA (Cargo)**
- Packing instruction (cargo aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

**IATA (Passenger)**
- Packing instruction (passenger aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

### 14.5 Environmental hazards

**ADN**
- Environmentally hazardous: yes

**ADR**
- Environmentally hazardous: yes

**RID**
- Environmentally hazardous: yes

**IMDG**
- Marine pollutant: yes

**IATA (Passenger)**
- Environmentally hazardous: yes
IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

<table>
<thead>
<tr>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Triclabendazole / Abamectin Formulation

Version 1.6
Revision Date: 27.08.2021
SDS Number: 5342053-00007
Date of last issue: 26.04.2021
Date of first issue: 05.12.2019

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H300: Fatal if swallowed.
H311: Toxic in contact with skin.
H330: Fatal if inhaled.
H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H373: May cause damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure
FOR-2011-12-06-1358: Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / TWA: Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELX - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Obsevable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous
Triclabendazole / Abamectin Formulation

Further information


Classification of the mixture:

- STOT RE 2: H373 Calculation method
- Aquatic Acute 1: H400 Calculation method
- Aquatic Chronic 1: H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN